Plexision completes development of PlexAPR, a rapid blood test to predict transplant rejection

PITTSBURGH--()--Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients has completed development of a six-hour blood test to predict organ transplant rejection - PlexAPR™. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance of organ health. To learn more, please visit

“Transplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes,” said Rajeev Sindhi, CEO of Plexision.

PlexAPR™ is based on the presentation of donor antigen by circulating antigen presenting cells, such as B-cells. The test readout is a personalized index, only applicable to the patient being tested. Patient samples will be tested at the company’s CLIA- and CAP-accredited reference laboratory in Pittsburgh.

Roughly 40,000 patients receive solid organ transplants each year in the US. A limited number of drugs are available to prevent organ rejection. Rapid non-invasive surveillance of organ health provided by Plexision can improve survival and quality of life after transplantation.

About Plexision: Plexision’s reference laboratory performs cell-based blood tests for personalized management of transplant rejection, infections in immunocompromised patients, and immune therapy in oncology. Transplant rejection testing services include the FDA-approved Pleximmune blood test to predict transplant rejection in children with liver or intestine transplants and the lab-developed Pleximark test to predict kidney transplant rejection. Tests that predict infection includes the lab-developed PlexCMV and the PlexCOVID-19 tests. These tests measure cell-mediated immunity to cytomegalovirus and the COVID-19 coronavirus, respectively. Plexision also performs custom R & D projects that require integration of cellular biomarker targets in all phases of development of drugs, vaccines, and gene therapy products, from pre-clinical to post-marketing. The company’s portfolio of cell-based blood tests can be adapted to assess disease risk for several immunological disorders and develop personalized dosing recommendations. The company’s reference laboratory in Pittsburgh, PA, is CLIA-approved, CAP-accredited and GMP-compliant. To learn more, visit or email or